在2023年泌尿生殖系统癌症研讨会上展示的1b/2期试验(NCT04300140),根据一项研究的1b期部分的研究结果,batiraxcept(AVB-S6-500)和卡博替尼(Cabometyx)的组合是安全的,并且在经过预处理的晚期或转移性透明细胞肾细胞癌(ccRCC)患者中产生了疗效。 Batiraxcept是一种重组融合蛋白,是一种高效且特异性一流的AXL抑制剂。
Our data suggest that the addition of AVB-S6-500 increased the therapeutic efficacy of Trastuzumab therapy in uterine serous cancers. Additional therapeutic and mechanistic experiments are ongoing.doi:10.1016/s0090-8258(22)01499-8J. TankouA. Oplt...
“Gaining Fast Track Designation is an important recognition of the potential that AVB-S6-500 has to offer to meet a critical unmet medical need for patients with recurrent ovarian cancer,” said Ray Tabibiazar, M.D., executive chairman of Aravive Biologics. “We look forward to initiating the...
免费查询更多avb-s6-500 抑制剂详细参数、实时报价、行情走势、优质商品批发/供应信息等,您还可以发布询价信息。
1889P Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear c... This Phase 2, multi-center, open-label study includes three parts: Part A) batiraxcept 15 mg/kg q2w in combination with cab...
AVB-S6-500 (AVB) is a novel AXL pathway inhibitor which binds to circulating Gas6 and inhibits ligand-dependent AXL signaling. In this phase Ib investigator-initiated trial (NCT04004442), we evaluated the safety, tolerability, pharmacodynamics, and preliminary antitumor efficacy of AVB with the ...
41TPS4599#Background:In clear cell renal cell carcinoma (ccRCC) the constitutive expression of hypoxia induced factor 1-伪 leads to increased expression of AXL. AXL overexpression has been associated with the development of resistance to VEGF inhibitors and suppression of the innate immune response ...
A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carci... 4511#Background:AXL is up-regulated by hypoxia-inducible factor-1 signaling in both VHL-deficient and hypoxic tumor cells and ...
Phase 1b study of batiraxcept (AVB-S6-500, BT) plus gemcitabine (G) and nab-paclitaxel (NP) as first-line treatment (1L) for advanced pancreatic adenocarcinoma (PDAC).261-492-3532-2370-7650-2700,613-615-646-4685-2805,613-135-244-3829-325,261-492-199-2823,261-492-5651-5482,261-...
A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carcinoma who have received front-line treatment (NCT04300140).41Background: AXL is up-regulated by hypoxia-inducible factor-1 signaling in ...